You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase 1b, Multicenter Study
|
|---|---|
| Published in |
Cancer Discovery, October 2018
|
| DOI | 10.1158/2159-8290.cd-18-0280 |
| Pubmed ID | |
| Authors |
Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi, Joseph J Drabick, Minal Barve, Gregory A Daniels, Deborah J Wong, Emmett V Schmidt, Albert F Candia, Robert L Coffman, Abraham C F Leung, Robert S Janssen |
| Abstract |
PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase 1b trial evaluated intratumoral SD-101, a synthetic CpG-oligonucleotide that stimulates Toll-like receptor 9 (TLR9), in combination with pembrolizumab in patients with unresectable or metastatic malignant melanoma. The most common adverse events related to SD-101 were injection site reactions and transient, mild-to-moderate "flu-like" symptoms. Among the 9 patients naïve to anti-PD-1 therapy, the overall response rate (ORR) was 78%. The estimated 12 month progression free survival (PFS) rate was 88%, and overall survival (OS) rate was 89%. Among 13 patients having prior anti-PD-1 therapy, the ORR was 15%. RNA profiling of tumor biopsies demonstrated increased CD8+ T cells, NK cells, cytotoxic cells, dendritic cells, and B cells. The combination of intratumoral SD-101 and pembrolizumab was well tolerated and induced broad immune activation in the tumor microenvironment with durable tumor responses in both peripheral and visceral lesions. |
X Demographics
The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 13 | 37% |
| Russia | 2 | 6% |
| Switzerland | 1 | 3% |
| Germany | 1 | 3% |
| United Kingdom | 1 | 3% |
| Australia | 1 | 3% |
| Japan | 1 | 3% |
| France | 1 | 3% |
| Unknown | 14 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 27 | 77% |
| Scientists | 4 | 11% |
| Science communicators (journalists, bloggers, editors) | 3 | 9% |
| Practitioners (doctors, other healthcare professionals) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 164 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 34 | 21% |
| Student > Ph. D. Student | 24 | 15% |
| Other | 18 | 11% |
| Student > Bachelor | 11 | 7% |
| Student > Master | 11 | 7% |
| Other | 17 | 10% |
| Unknown | 49 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 27 | 16% |
| Medicine and Dentistry | 27 | 16% |
| Immunology and Microbiology | 17 | 10% |
| Agricultural and Biological Sciences | 14 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 8% |
| Other | 12 | 7% |
| Unknown | 54 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 180. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2023.
All research outputs
#226,729
of 25,734,859 outputs
Outputs from Cancer Discovery
#85
of 4,153 outputs
Outputs of similar age
#4,564
of 355,970 outputs
Outputs of similar age from Cancer Discovery
#2
of 103 outputs
Altmetric has tracked 25,734,859 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,153 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 355,970 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 103 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.